Qiagen NV (NYSE:QGEN) Receives Average Recommendation of “Buy” from Analysts

Qiagen NV (NYSE:QGEN) has been assigned a consensus recommendation of “Buy” from the twelve research firms that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $41.67.

QGEN has been the subject of a number of research analyst reports. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a report on Wednesday, May 8th. Goldman Sachs Group reaffirmed a “buy” rating on shares of Qiagen in a report on Tuesday, May 7th. Zacks Investment Research raised shares of Qiagen from a “sell” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Tuesday, April 16th. UBS Group began coverage on shares of Qiagen in a report on Friday, March 15th. They issued a “neutral” rating and a $42.00 target price for the company. Finally, Barclays raised their target price on shares of Qiagen from $43.00 to $45.00 and gave the company an “overweight” rating in a report on Friday, June 21st.

QGEN traded up $0.07 during trading on Wednesday, reaching $39.99. 24,909 shares of the company traded hands, compared to its average volume of 1,235,277. The company has a current ratio of 1.69, a quick ratio of 1.52 and a debt-to-equity ratio of 0.54. Qiagen has a 12-month low of $32.33 and a 12-month high of $41.55. The business’s fifty day simple moving average is $39.46. The stock has a market capitalization of $8.98 billion, a P/E ratio of 29.78, a P/E/G ratio of 2.47 and a beta of 0.84.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.01. Qiagen had a net margin of 12.45% and a return on equity of 12.22%. The business had revenue of $348.70 million during the quarter, compared to analyst estimates of $351.68 million. During the same period last year, the firm posted $0.26 EPS. The company’s revenue was up 1.5% on a year-over-year basis. On average, equities research analysts predict that Qiagen will post 1.43 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of QGEN. Campbell & CO Investment Adviser LLC bought a new stake in Qiagen in the first quarter worth $229,000. PNC Financial Services Group Inc. lifted its position in Qiagen by 1.8% in the first quarter. PNC Financial Services Group Inc. now owns 205,337 shares of the company’s stock worth $8,353,000 after buying an additional 3,609 shares during the last quarter. Cornerstone Advisors Inc. bought a new stake in Qiagen in the first quarter worth $44,000. D. E. Shaw & Co. Inc. lifted its position in Qiagen by 19.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,756,276 shares of the company’s stock worth $60,489,000 after buying an additional 290,673 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Qiagen by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 584,780 shares of the company’s stock worth $20,145,000 after buying an additional 47,932 shares during the last quarter. 63.22% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Read More: What is the Federal Reserve?

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.